Comparison of the registration process of the Medicines Control Authority of Zimbabwe with Australia, Canada, Singapore, and Switzerland: Benchmarking best practices
Author
Sithole, Tariro
Salek, Sam
Mahlangu, Gugu
Walker, Stuart
Attention
2299/25299
Abstract
Background: Benchmarking regulatory systems of low- and middle-income countries with mature systems provides an opportunity to identify gaps, enhance review quality, and reduce registration timelines, thereby improving patients’ access to medicines. The aim of this study was to compare the medicines registration process of the Medicines Control Authority of Zimbabwe (MCAZ) with the regulatory processes in Australia, Canada, Singapore, and Switzerland. Methods: A questionnaire that standardizes the review process, allowing key milestones, activities and practices of the five regulatory authorities was completed by a senior member of the divisions responsible for issuing marketing authorizations. Results: The MCAZ has far fewer resources than the regulatory authorities in the comparator countries, but employs three review models, which is in line with international best practice. The MCAZ registration process is similar to the comparator countries in key milestones monitored, but differs in the target timelines for these milestones. The MCAZ is comparable to the comparator authorities in implementing the majority of good review practices, although it significantly lags behind in transparency and communication. Conclusion: This study identified the MCAZ strengths and opportunities for improvement, which if implemented, will enable the achievement of its vision to be a leading regulatory authority in Africa.
Publication date
2021-10-20Published in
Expert Review of Clinical PharmacologyPublished version
https://doi.org/10.1080/17512433.2022.1987883Other links
http://hdl.handle.net/2299/25299Metadata
Show full item recordRelated items
Showing items related by title, author, creator and subject.
-
Off-Label and Unlicensed Medicines' Related Problems in Paediatric In-Patients
Elhijazi, Wijdan (2018-10-15)Background: Current legislations such as paediatric investigation plan (PIP) require pharmaceutical companies seeking marketing authorisation for a new medicine to provide evidence of studies in paediatrics to justify the ... -
Identifying counterfeit medicines using near infrared spectroscopy
Moffat, Anthony C.; Watt, Robert A.; Assi, Sulaf (2010)Counterfeit medicines are a growing threat to public health across the world and screening methods are needed to allow their rapid identification. A counterfeiter must duplicate both the physical characteristics and the ... -
The SEE-IT Trial: emergency medical services S treaming E nabled E valuation I n T rauma: study protocol for an interventional feasibility randomised controlled trial
on behalf of the SEE-IT Trial Group; Ollis, Lucie; Skene, Simon S; Williams, Julia; Lyon, Richard; Taylor, Cath; Bennett-Eastley, Kate; Cropley, Mark; Gage, Heather; Holah, Janet; Maben, Jill; Magnusson, Carin; Mortimer, Craig; Munro, Scott (2023-04-24)Introduction: Accurate and timely dispatch of emergency medical services (EMS) is vital due to limited resources and patients’ risk of mortality and morbidity increasing with time. Currently, most UK emergency operations ...